Advertisement
Organisation › Details
Roche Diabetes Care AG
Roche Diabetes Care is a pioneer in the development of blood glucose monitoring systems and a global leader for diabetes management systems and services. For more than 40 years, the Accu-Chek brand has been dedicated to enabling people with diabetes to live life as normally and actively as possible as well as to empowering healthcare professionals to manage their patients’ condition in an optimal way. Today, the Accu-Chek portfolio offers people with diabetes and healthcare professionals innovative products and impactful solutions for convenient, efficient and effective diabetes management, spanning from blood glucose monitoring through information management to insulin delivery. The Accu-Chek brand encompasses blood glucose meters, insulin delivery systems, lancing devices, data management systems and education programs – contributing to an improved medical outcome. *
Start | 2011-04-23 existent | |
Group | Roche (Group) | |
Industry | glucose metering device | |
Industry 2 | Accu-Chek Aviva blood glucose meter | |
Person | Gmuender, Marcel (Roche 201706 Global Head Diabetes Care) | |
Region | Burgdorf BE | |
Country | Switzerland | |
Street | 190 Kirchbergstr. | |
City | 3401 Burgdorf BE | |
Tel | +41-34-424-2424 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: mySugr GmbH. (6/30/17). "Press Release: mySugr Joins the Roche family". San Diego, CA. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Roche (Group)
- [1] Roche. (4/11/24). "Press Release: Roche Granted FDA Breakthrough Device Designation for Blood Test to Support Earlier Alzheimer's Disease Diagnosis". Basel....
- [2] Freenome, Inc.. (2/15/24). "Press Release: Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection". South San Francisco, CA....
- [3] PathAI Inc.. (2/13/24). "Press Release: PathAI Announces Exclusive Collaboration with Roche Tissue Diagnostics to Advance AI-enabled Interpretation for Companion Diagnostics". Boston, MA....
- [4] Repare Therapeutics Inc.. (2/12/24). "Press Release: Repare Therapeutics to Regain Global Rights to Camonsertib". Cambridge, MA & Montréal....
- [5] Hookipa Pharma Inc.. (1/29/24). "Press Release: Hookipa Pharma Provides Update on Business Priorities and Oncology Partnership Programs". New York, NY & Vienna....
- [6] Repare Therapeutics Inc.. (1/25/24). "Press Release: Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment". Cambridge, MA & Montréal....
- [7] Roche Deutschland Holding GmbH. (1/10/24). "Press Release: Prof. Hagen Pfundner wird zum 1. Mai 2024 Vorsitzender der Roche Deutschland Holding GmbH"....
- [8] Remix Therapeutics, Inc.. (1/3/24). "Press Release: Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing". Watertown, MA....
- [9] MediLink Therapeutics (Suzhou) Co., Ltd.. (1/2/24). "Press Release: MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to Develop Next-generation Antibody Drug Conjugate in Oncology". Suzhou....
- [10] Roche. (12/29/23). "Press Release: Roche Enters into a Definitive Agreement to Acquire LumiraDx's Point of Care Technology Combining Multiple Diagnostic Modalities on a Single Platform". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top